Despite VTC’s pronounced affinity for BCL-2 over BCL-XL and BCL-W, thrombocytopenia remains a prevalent side effect during treatment (Delou et al., 2019; Sarkozy and Ribrag, 2020; Van Wagoner et al., 2023). Here, BCL2L1 is linked to Thrombocytopenia.